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Risk of Oral Contraceptives and
Recency of Market Introduction
To the Editors:
In the recent exchange of views on the impact of the
epidemiologic studies on deep vein thrornbosis and
third generation contraceptives,1'2 the earlier publica-
tion by Lewis et al. from the Transnational Study3
plays an important role. It indicated that the risks
increase according to the recency of market introduc-
tion of the oral contraceptive.3 However, the impor-
tant Figure l, which graphically shows increasing
odds ratios by year of introduction, was based only on
the subset of women aged 25-44.3 The data of the
women aged 16-24 were left out, which amounts to
one-third of the cases and close to half of the controls
who used oral contraceptives. The same publication
contains data and odds ratios for all ages (16-44),
wherein no trend is apparent. The authors stated that
Table. Relative risk of venous thromboembolism in
women aged 16-24 years; data recalculated from published
tables of the Transnational Study3
Cases Controls OR
Levonorgestrel
Gestodene
Desogestrel (30 pg)
Desogestrel (20 pg)
Norgestimate
Other OC (oestradiol <50 pg)
OC with oestradiol >50 pg
Progesterone-only puls (POP)
27
24
32
2
8
10
6
4
104
66
48
20
18
30
12
8
1.0
1.4
2.6
0.4
1.7
1.3
1.9
1.9
Risk Ratio
2.6
1.9
1.4
1.7
o - ! -·'· — '---
Levonorgestrel
1972/74
POP Desogestrel (30) Gestodene Norgestimate Desogestrel (20)
1971/74 1981 1986 1986/92 1992
Type of oral contraceptive and year of market introduction
Figure. Risk ratios of combined oral contraceptives compared with levonorgestrel for women aged 16-24 by year of market
introduction; recalculated from published data of Transnational Study.3
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they had restricted their analysis to the 25-44 age
bracket because among the younger women, too
many would have been taking the newer pills—
despite their demonstration, further in the paper, that
more than half of contraceptive-using women in the
age group 16-24 used older types of pills.
Fortunately, it was possible to reconstruct the data
for the ages 16-24 by subtracting the table for the ages
25-44 from the overall table (Tables 2 and 3), and
recalculate the odds ratios for the ages 16-24. The
data for the youngest women are the most relevant,
since we expect most of the new users among them.
When doing the same analyses äs the authors, we find
the following Table and Figure. The trend of the odds
ratios among women aged 16-24 indicates an overall
higher risk of third generation products, but almost
an inverse relation with year of introduction. This
denies the conclusion of the authors, and at the same
time explains why the trend is not present in the
complete data from the Transnational Study (Table
2). Moreover, inclusion of older types of pills in the
figure—introduced before levonorgestrel-containing
pills, and for which the recency argument does not
hold—would lead to a V-shaped curve, indicating that
the higher risks of older preparations have indeed re-
turned.
While we greatly commend the authors of the
Transnational Study for their open style of publica-
tion, which permits these recalculations, there is the
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distinct possibility that they have fallen into the trap
of Publishing the most pleasing subgroup analysis.
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RESPONSE TO THE EDITOR
The Role of Bias in Observational Studies
on Oral Contraceptives
We would like to thank Drs. Weiss1 and Vanden-
broucke et al.2 for their commentaries. These focus
mainly on a criticism related to our using only se-
lected portions of the data, namely data on women
aged 25-44, in our analysis.3 We will explain the ra-
tionale more clearly than was done in our article.
This group was selected for two reasons. First, we
wanted to have a group which is likely to have been
exposed to all oral contraceptives on the market, in-
cluding the older preparations. Second, the phenom-
enon of attrition of susceptibles (or, conversely, the
existence of a stable group of "healthy users") could
only be demonstrated in a group in which high-risk
individuals have already been removed (i.e. a stable
group of levonorgestrel users , or are in the process of
being removed (i.e. groups taking newer proge-
stagens), which again leaves us with the older age
group. Because our reference group was chosen to be
levonorgestrel, we clearly need a population with ex-
posures of sufficient duration to have formed a stable
healthy user group. At the time of the analysis, we
feit that this Status can only occur in women past the
age of 25, whose potential exposure experience ranges
from about 10 years to 30 years.
This rationale has been confirmed empirically to be
appropriate. A comparison of duration of use of two
progestagens (levonorgestrel and gestodene) in con-
trols stratified by the two age groups (Table) shows
that duration of current use is almost the same in
both age groups for gestodene, but about 30% of
women aged 25-44 years were at the time of inter-
view using levonorgestrel for over 6 years compared
with only 8% of 16-24 year old women. This means
that there is an appreciably larger proportion of
